Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3662569> ?p ?o }
Showing triples 1 to 43 of
43
with 100 triples per page.
- Q3662569 subject Q10090201.
- Q3662569 subject Q7145095.
- Q3662569 subject Q8255962.
- Q3662569 abstract "Peginesatide (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of peginesatide from the market. On June 16, 2014, Affymax and Takeda issued a press release stating that Takeda will work with the FDA to withdraw the peginesatide New Drug Application.Two randomized controlled trials published in 2013 found that the effectiveness of peginesatide was not inferior to epoetin for patients receiving dialysis (the EMERALD study), or to darbepoetin for patients with chronic kidney disease who were not receiving dialysis (the PEARL study). However, the safety endpoint of cardiovascular events and death was worse for peginesatide than for darbepoetin in the PEARL study.".
- Q3662569 atcPrefix "B03".
- Q3662569 atcSuffix "XA04".
- Q3662569 casNumber "913976-27-9".
- Q3662569 casSupplemental "(acetate)".
- Q3662569 chEBI "66889".
- Q3662569 iupacName "Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, diester with 21N6,21'N6-{[(N2,N6-dicarboxy-(L)-lysyl-β-alanyl)imino]bis(1-oxo-2,1-ethanediyl)}bis[N-acetylglycylglycyl-(L)-leucyl-(L)-tyrosyl-(L)-alanyl-(L)-cysteinyl-(L)-histidyl-(L)-methionylglycyl-(L)-prolyl-(L)-isoleucyl-(L)-threonyl-3-(1-naphthalenyl)-(L)-alanyl-(L)-valyl-(L)-cysteinyl-(L)-glutaminyl-(L)-prolyl-(L)-leucyl-(L)-arginyl-N-methylglycyl-(L)-lysinamide]cyclic (6→15),(6'→15')-bis(disulfide)".
- Q3662569 wikiPageExternalLink london-2012-holding-back-the-hematide.
- Q3662569 wikiPageWikiLink Q10090201.
- Q3662569 wikiPageWikiLink Q14852026.
- Q3662569 wikiPageWikiLink Q202301.
- Q3662569 wikiPageWikiLink Q2035485.
- Q3662569 wikiPageWikiLink Q212527.
- Q3662569 wikiPageWikiLink Q212646.
- Q3662569 wikiPageWikiLink Q2178381.
- Q3662569 wikiPageWikiLink Q410083.
- Q3662569 wikiPageWikiLink Q4926095.
- Q3662569 wikiPageWikiLink Q5383794.
- Q3662569 wikiPageWikiLink Q5445.
- Q3662569 wikiPageWikiLink Q640448.
- Q3662569 wikiPageWikiLink Q682252.
- Q3662569 wikiPageWikiLink Q6823893.
- Q3662569 wikiPageWikiLink Q7145095.
- Q3662569 wikiPageWikiLink Q736715.
- Q3662569 wikiPageWikiLink Q824258.
- Q3662569 wikiPageWikiLink Q8255962.
- Q3662569 wikiPageWikiLink Q837174.
- Q3662569 wikiPageWikiLink Q899133.
- Q3662569 atcPrefix "B03".
- Q3662569 atcSuffix "XA04".
- Q3662569 casNumber "913976".
- Q3662569 chebi "66889".
- Q3662569 iupacName "Poly, α-hydro-ω-methoxy-, diester with 21N6,21'N6-{[imino]bis}bis[N-acetylglycylglycyl-(L)-leucyl-(L)-tyrosyl-(L)-alanyl-(L)-cysteinyl-(L)-histidyl-(L)-methionylglycyl-(L)-prolyl-(L)-isoleucyl-(L)-threonyl-3--(L)-alanyl-(L)-valyl-(L)-cysteinyl-(L)-glutaminyl-(L)-prolyl-(L)-leucyl-(L)-arginyl-N-methylglycyl-(L)-lysinamide] cyclic ,-bis".
- Q3662569 type ChemicalSubstance.
- Q3662569 type Drug.
- Q3662569 type ChemicalObject.
- Q3662569 type Thing.
- Q3662569 type Q8386.
- Q3662569 comment "Peginesatide (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of peginesatide from the market.".
- Q3662569 label "Peginesatide".